The Efficacy of Pancreatic Duct Stenting With Rectal Indomethacin in Preventing Post-ERCP Pancreatitis
Post-ERCP Pancreatitis, Pancreatitis, Acute Necrotizing
About this trial
This is an interventional treatment trial for Post-ERCP Pancreatitis
Eligibility Criteria
Inclusion Criteria:
Age over 18 years old,gender is not limited; Preoperative blood amylase is normal; PEP risk factors during surgery:difficulty in intubation,needle knife incision,intraoperative intubation into the pancreatic duct more than 3 times,the contrast agent in the pancreatic duct is filled; The research procedure is willing to be followed and the informed consent is signed.
Exclusion Criteria:
Myocardial infarction occurred within 3 months; Insufficiency of renal function; Conventional gastrectomy; Preoperative state of shock,such as hypotension(systolic blood pressure less than 90mmHg); Pregnancy and lactation; Allergic to NSAIDs drugs; Partially or completely restricted in the ability to exercise consciousness,without self-determination ability; Are participating in other clinical observation trials or have participated in other clinical trials within 60 days; Cases considered unsuitable by the investigator.
Sites / Locations
- Hangzhou First People's Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
indomethacin with stenting group
indomethacin group
Pancreatic duct stenting and rectal indomethacin 100mg at preoperative 30min in 100 patients
Rectal indomethacin 100mg at preoperative 30min in 100 patients